An observational study in Gastro-enteropancreatic Neuroendocrine Tumor, sponsored by Novartis Pharmaceuticals. Completed at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by Novartis Pharmaceuticals · Observational
The aim of this study was to assess patient characteristics and treatment patterns of gastro-enteropancreatic neuroendocrine tumor (GEP-NET) patients who received PRRT in German routine care.
32 studies on the registry are indexed under Gastro-enteropancreatic neuroendocrine tumor; 12 are open to participants now.
Browse Gastro-enteropancreatic neuroendocrine tumor studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.
Exclusion criteria:
Adult GEP-NET patients who received PRRT in German routine care.
Baseline Demographics
Time frame: Baseline
Number of Patients by Tumor Status
Time frame: Baseline
Duration Between Initial Diagnosis and Initiation of Primary PRRT
Time frame: Baseline
Number of Patients by PRRT Line of Therapy
Time frame: Approximately 1 year
Number of Patients by Type of PRRT Received
Time frame: Approximately 1 year
PRRT Dosage
Time frame: Approximately 1 year
Number of Patients by Treatment Interval
Time frame: Approximately 1 year
Number of Patients by Co-medication
Time frame: Approximately 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gastro-enteropancreatic neuroendocrine tumor→
Novartis Pharmaceuticals